Objective: To describe the surgical technique of botulinum-A toxin injection into the cremasteric muscles of a 26-year-old male with bilateral cremasteric muscle spasms causing significant pain and limitation of activity. This pain has been refractory to multiple previous therapies, including inguinal nerve blocks and bilateral orchidopexies with cremasteric muscle lysis. Multiple imaging modalities revealed no obvious pathology for this significant bilateral pain. Genitourinary examination revealed hyper-retractile testes with changes consistent with bilateral orchidopexies and was otherwise normal.
Material And Methods: The patient has undergone 3 outpatient staged injections of botulinum-A toxin into the bilateral cremasteric muscles after spermatic cord block with 1% lidocaine. One hundred units of botulinum-A toxin mixed into 10 mL of sterile normal saline were used for each injection staged 6 weeks apart.
Results: The patient tolerated all injections without apparent side effects. After the first injection into his left side, his baseline pain scores were reduced from 8 out of 10 to 3 out of 10 on a standard 10-point pain scale. He reported maximal efficacy 2 weeks after each injection, with dissipation over 4-6 weeks. After 2 left-sided and 1 right-sided injections, his baseline pain was 2 to 4 of 10, equal bilaterally, and he was back to rigorous activity with some limitations.
Conclusion: Direct injection of botulinum-A toxin into the cremasteric muscle is a viable treatment option for the rare patient with debilitating and painful cremasteric spasms refractory to other therapies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.urology.2011.03.011 | DOI Listing |
Urogynecology (Phila)
February 2025
From the Departments of Gynecology and Obstetrics.
Importance: Patients deciding between advanced therapies for overactive bladder syndrome may be interested to know the likelihood of treatment crossover after sacral neuromodulation, intradetrusor OnabotulinumtoxinA, or percutaneous tibial nerve stimulation. Treatment crossover was defined as a switch from one advanced therapy to another.
Objectives: The aim of this study was to estimate the rate of treatment crossover after each advanced therapy for nonneurogenic overactive bladder syndrome.
Int J Colorectal Dis
January 2025
Department of Surgery, Azienda Sanitaria Provinciale Crotone, 88900, Crotone, Italy.
Purpose: Chronic constipation is a common symptom. Constipation due to pelvic floor disorders remain a therapeutic challenge. Biofeedback therapy is considered as the first-choice treatment for pelvic floor disorders, whenever dedicated expertise is available.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Rehabilitation Medicine, Hebei General Hospital, Shijiazhuang, Hebei, China.
Rationale: Steven-Johnson syndrome (SJS) is characterized by severe illness, rapid progression, and high mortality rates, with the vast majority of cases induced by medications. Botulinum toxin, a neurotoxin produced by Clostridium botulinum, has not been reported in the literature as a causative agent of SJS.
Patient Concerns: A 56-year-old male patient, who underwent surgery for cerebral hemorrhage, developed widespread patchy annular papules following the injection of botulinum toxin into the masseter muscle.
Arch Dermatol Res
January 2025
Department of Dermatology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
Acne vulgaris is a common and challenging condition to treat. To assess the effect of botulinum toxin type A (BTX-A) in the treatment of mild to moderate acne vulgaris. This study included 30 patients with mild to moderate acne vulgaris treated with intradermal injections of diluted BTX-A (microbotox) on the cheek in a regular grid pattern using very small droplets (microbotox).
View Article and Find Full Text PDFBMC Ophthalmol
January 2025
Department of Ophthalmology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Background: This study investigates the effect of botulinum toxin A on lipid layer thickness (LLT) and blink dynamics in patients with benign essential blepharospasm (BEB) compared to dry eye disease (DED) patients.
Methods: We reviewed the medical records of patients with dry eye disease (DED) and BEB treated with botulinum toxin A (BoT A) injections. Data on demographics, lipid layer thickness (LLT), meiboscore, and blink dynamics measured using a LipiView II interferometer before and 2 months after BoT A were collected.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!